The journal Psychopharmacology has retracted three papers on MDMA-assisted therapy for PTSD, all based on Lykos Therapeutics trial data. The three notices cover a pooled phase 2 follow-up paper, a phase 3 design-and-rationale paper, and a paper on reuptake-inhibitor discontinuation.
The retraction notes themselves are blunt. The editors say they were informed of protocol violations amounting to unethical conduct at the MP4 study site, that the authors knew about those violations when they submitted the papers, and that they neither disclosed that information to the journal nor removed data generated by that site from their analyses. The notices also say the authors did not fully declare a potential competing interest, noting that several authors were affiliated with MAPS or MAPS PBC while MAPS funded the work, supplied the MDMA, and MAPS PBC organized the trial.
What is new is not a fresh efficacy readout. It is a formal decision to pull three papers out of the peer-reviewed literature after the fact. That matters because the MDMA program was already under heavy FDA scrutiny by the June 4, 2024 advisory-committee meeting, where the panel voted 2-9 against whether the available data showed effectiveness and 1-10 against whether the benefits outweighed the risks.
Lykos used its own June 4 update to stress that the advisory-committee vote was nonbinding and that the FDA makes the final approval decision. That is true procedurally. But the journal retractions make the company's credibility problem worse, not better.
What this means
The retractions do not change the underlying trial data. The results are what they are. What the retractions do change is the published record. Three peer-reviewed papers that had been cited in support of MDMA therapy's evidence base are now out of the literature.
That leaves Lykos trying to defend the program with less clean published support after an FDA advisory committee already voted overwhelmingly against the application. Three retracted papers do not settle the efficacy debate on their own, but they narrow the field's ability to point to the published record as if the controversy were mostly behind it.
The broader question, whether MDMA-assisted therapy works, remains open. The retracted papers were not the only evidence. But the regulatory and credibility burden around this program just got heavier.